Mistletoe Therapy / Iscador

Key Components

• Subcutaneous injection 2–3x per week (self-administered or clinic)
• Starting dose is very low, titrated up over weeks based on local reaction
• Local skin reaction (redness, warmth) is desired and indicates immune response
• Brand matters — Iscador (Weleda), Helixor, or Eurixor are most studied
• Different host trees (oak, apple, pine, elm) used for different cancer types
• Always used alongside conventional treatment, not as replacement

How It Works

Mistletoe lectins (ML-I, ML-II, ML-III) are the primary active compounds. They inhibit protein synthesis in cancer cells (ribosome-inactivating proteins), induce apoptosis, and stimulate the immune system by increasing Natural Killer (NK) cell activity and cytokine production (IL-1, IL-6, TNF-alpha). Viscotoxins have direct cytolytic effects. Mistletoe also appears to improve tumour oxygenation and reduce DNA damage from chemotherapy, potentially improving quality of life and reducing treatment side effects.

Mistletoe therapy has the strongest evidence base among complementary cancer therapies. A 2021 Cochrane review found mistletoe to improve quality of life and reduce chemotherapy side effects with moderate evidence. A randomised trial (2020, integrative oncology journal) showed improved 1-year survival in pancreatic cancer. Multiple systematic reviews confirm its immunostimulatory effects. It is listed in the S3 Guideline of the German Cancer Society as an evidence-based complementary therapy for quality of life improvement.

• Local injection site reactions (redness, itching) are normal and expected
• Rare: systemic allergic reactions — begin with very low dose
• Should not be used in severe autoimmune conditions (may over-stimulate immune system)
• Avoid in organ transplant recipients on immunosuppressants
• Use standardised pharmaceutical preparations — not wild-harvested berries (toxic)
• Obtain from a trained integrative oncologist or naturopath